Colonial Trust’s Amylyx Pharmaceuticals AMLX Stock Holding History

Colonial Trust’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-86	Closed	-$1.27K	–	987
2023 Q4	$1.27K	Hold	86	–	–	﹤0.01%	927
2023 Q3	$1.8K	Buy	+86	New	+$1.82K	﹤0.01%	911

Other funds holding AMLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Colonial Trust's AMLX Position: Q1 2024 in Review

Colonial Trust sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 86 shares — an estimated $1.27K sold.

Colonial Trust first reported a position in AMLX in Q3 2023 and held it in 2 quarters. The position peaked at $1.8K in Q3 2023. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

Colonial Trust reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Colonial Trust sold 86 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $1.27K.
Colonial Trust first reported a position in Amylyx Pharmaceuticals in Q3 2023 and held it in 2 quarters.
Colonial Trust's Amylyx Pharmaceuticals position peaked at $1.8K in Q3 2023.
143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Colonial Trust's 13F filing for Q1 2024, filed 14 May 2024.